Sunshine Biopharma, Inc. Narrows Kilogram Manufacturing Options for Adva-27a Breast Cancer Drug Candidate to Three Suppliers
5/1/2013 11:55:21 AM
More...
|
Sunshine Biopharma, Inc. HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
4/9/2013 11:44:00 AM
More...
|
Sunshine Biopharma, Inc. Commences Negotiations With Contract Manufacturing Organizations for Production of Its Multidrug-Resistant Breast Cancer Drug, Adva-27a
3/14/2013 9:19:51 AM
More...
|
Sunshine Biopharma, Inc. Reports on IND Research for Its Novel Breast Cancer Drug Candidate, Adva-27a
2/26/2013 9:38:25 AM
More...
|
Advanomics Corporation, the Parent Company of Sunshine Biopharma, Inc., Files a New Patent Application for Its Multidrug Resistance Adva-27a Anticancer Compound
1/14/2013 11:33:46 AM
More...
|
Sunshine Biopharma, Inc. Completes Another IND-Enabling Study: Adva-27a is Found to be Effective Against Multidrug Resistant Uterine Cancer Cells
12/10/2012 9:21:08 AM
More...
|
Sunshine Biopharma, Inc. Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a
12/4/2012 10:19:07 AM
More...
|
Advanomics Corporation, the Parent Company of Sunshine Biopharma, Inc., Completes Acquisition of Adva-27a Patents
11/27/2012 10:08:01 AM
More...
|
Sunshine Biopharma, Inc. Receives Scale-Up Manufacturing Protocol for Its Lead Anti-Cancer Compound, Adva-27a
10/9/2012 9:48:45 AM
More...
|
Sunshine Biopharma, Inc.'s Adva-27a Preclinical Research Results to be Published in October Issue of Anticancer Research
9/25/2012 9:03:06 AM
More...
|
|